How many institutions held CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share in Q2 2022?

111 institutional investors reported CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share for Q2 2022. Use the holders table for investor-level position and value details.

C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Q: What does CUSIP 12529R107 represent in this 13F holders report?

CUSIP 12529R107 is the security identifier for CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

CUSIP: 12529R107

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 88,353,400
Total 13F shares: 39,425,650
Share change: +2,166,392
Total reported value: $297,247,580
Put/Call ratio: 0%
Price per share: $7.54
Number of holders: 111
Value change: -$39,977,861
Number of buys: 65
Number of sells: 65

Quarterly Holders Quick Answers

What is CUSIP 12529R107?
CUSIP 12529R107 identifies CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2022
Previous quarter: Q1 2022

Recent filing periods for CUSIP 12529R107:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of CCCC - C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
RTW INVESTMENTS, LP	13F	Company	5.1%	4,531,982	$109,946,000	—	31 Mar 2022	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	5%	4,377,372	$106,195,000	—	31 Mar 2022	13F
BlackRock Finance, Inc.	13F	Company	3.6%	3,139,990	$76,177,000	—	31 Mar 2022	13F
STATE STREET CORP	13F	Company	2.5%	2,227,759	$54,045,000	—	31 Mar 2022	13F
PERCEPTIVE ADVISORS LLC	13F	Company	2.4%	2,082,723	$50,526,000	—	31 Mar 2022	13F
VANGUARD GROUP INC	13F	Company	2.3%	2,022,142	$49,057,000	—	31 Mar 2022	13F
ArrowMark Colorado Holdings LLC	13F	Company	2.2%	1,909,023	$46,313,000	—	31 Mar 2022	13F
Bain Capital Life Sciences Investors, LLC	13F	Company	1.9%	1,642,210	$39,840,000	—	31 Mar 2022	13F
WASATCH ADVISORS LP	13F	Company	1.7%	1,538,525	$37,325,000	—	31 Mar 2022	13F
PICTET ASSET MANAGEMENT SA	13F	Company	1.3%	1,131,441	$27,449,000	—	31 Mar 2022	13F
JANUS HENDERSON GROUP PLC	13F	Company	1.2%	1,086,782	$26,368,000	—	31 Mar 2022	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	1.1%	990,941	$24,040,000	—	31 Mar 2022	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.76%	667,819	$16,201,000	—	31 Mar 2022	13F
MORGAN STANLEY	13F	Company	0.74%	657,572	$15,954,000	—	31 Mar 2022	13F
PURA VIDA INVESTMENTS, LLC	13F	Company	0.71%	624,860	$15,159,000	—	31 Mar 2022	13F
FMR LLC	13F	Company	0.68%	599,281	$14,539,000	—	31 Mar 2022	13F
Point72 Asset Management, L.P.	13F	Company	0.57%	503,888	$12,224,000	—	31 Mar 2022	13F
Paradigm Biocapital Advisors LP	13F	Company	0.57%	499,496	$12,118,000	—	31 Mar 2022	13F
Alain J. Cohen	3/4/5	Director	— class O/S missing	1,805,252	$11,770,243	—	04 Apr 2022	3/4/5
Commodore Capital LP	13F	Company	0.54%	481,094	$11,671,000	—	31 Mar 2022	13F
Nuveen Asset Management, LLC	13F	Company	0.48%	420,454	$9,771,000	—	31 Mar 2022	13F
Nextech Invest Ltd.	13F	Company	0.43%	375,857	$9,118,000	—	31 Mar 2022	13F
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	0.41%	362,528	$8,795,000	—	31 Mar 2022	13F
CLOUGH CAPITAL PARTNERS L P	13F	Company	0.4%	356,181	$8,641,000	—	31 Mar 2022	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	0.4%	353,912	$8,586,000	—	31 Mar 2022	13F
NORTHERN TRUST CORP	13F	Company	0.4%	349,262	$8,474,000	—	31 Mar 2022	13F
UBS Group AG	13F	Company	0.37%	329,578	$7,995,000	—	31 Mar 2022	13F
PFM Health Sciences, LP	13F	Company	0.32%	284,772	$6,909,000	—	31 Mar 2022	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.31%	273,137	$6,627,000	—	31 Mar 2022	13F
EcoR1 Capital, LLC	13F	Company	0.23%	200,000	$4,852,000	—	31 Mar 2022	13F
Soleus Capital Management, L.P.	13F	Company	0.19%	166,736	$4,045,000	—	31 Mar 2022	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.16%	144,721	$3,511,000	—	31 Mar 2022	13F
Elena Prokupets	3/4/5	Director	— class O/S missing	534,807	$3,486,942	—	27 Sep 2021	3/4/5
Invesco Ltd.	13F	Company	0.16%	138,412	$3,358,000	—	31 Mar 2022	13F
Rafferty Asset Management, LLC	13F	Company	0.15%	135,392	$3,285,000	—	31 Mar 2022	13F
Alyeska Investment Group, L.P.	13F	Company	0.15%	131,250	$3,184,000	—	31 Mar 2022	13F
Bank of New York Mellon Corp	13F	Company	0.14%	127,072	$3,083,000	—	31 Mar 2022	13F
Mariner, LLC	13F	Company	0.14%	125,030	$3,033,000	—	31 Mar 2022	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.14%	119,789	$2,906,000	—	31 Mar 2022	13F
Cypress Point Wealth Management, LLC	13F	Company	0.13%	118,573	$2,877,000	—	31 Mar 2022	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.13%	114,931	$2,788,000	—	31 Mar 2022	13F
CITADEL ADVISORS LLC	13F	Company	0.12%	108,229	$2,626,000	—	31 Mar 2022	13F
TD ASSET MANAGEMENT INC	13F	Company	0.12%	107,153	$2,600,000	—	31 Mar 2022	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.12%	103,778	$2,517,000	—	31 Mar 2022	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.1%	89,662	$2,175,000	—	31 Mar 2022	13F
Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group	13F	Company	0.1%	85,000	$2,062,100	—	31 Mar 2022	13F
MANUFACTURERS LIFE INSURANCE COMPANY, THE	13F	Company	0.1%	84,966	$2,048,154	—	31 Mar 2022	13F
JPMORGAN CHASE & CO	13F	Company	0.08%	69,420	$1,684,000	—	31 Mar 2022	13F
Bellevue Group AG	13F	Company	0.06%	54,500	$1,322,000	—	31 Mar 2022	13F
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	13F	Company	0.05%	47,985	$1,164,000	—	31 Mar 2022	13F

Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) as of Q2 2022

As of 30 Jun 2022, C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) was held by 111 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 39,425,650 shares. The largest 10 holders included ArrowMark Colorado Holdings LLC, WASATCH ADVISORS INC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., RTW INVESTMENTS, LP, VANGUARD GROUP INC, Bain Capital Life Sciences Investors, LLC, PICTET ASSET MANAGEMENT SA, JANUS HENDERSON GROUP PLC, and PERCEPTIVE ADVISORS LLC. This page lists 111 institutional shareholders reporting positions in this security for the Q2 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders

120

Q2 2022 holders

111

Holder diff

-9

Investor	Q1 2022 Shares	Q2 2022 Shares	Share Diff	Share Chg %	Q1 2022 Value $	Q2 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.